Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival

Dose-Dependent Induction of an Idiotypic Cascade by Anti-Glycosaminoglycan Monoclonal Antibody in apoE−/− Mice: Association with Atheroprotection

(2017) Roger Sarduy et al.   Frontiers in Immunology

Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2

(2016) Nikolai Siebert et al.   mAbs

Arresting progressive atherosclerosis by immunization with an anti-glycosaminoglycan monoclonal antibody in apolipoprotein E-deficient mice

(2015) Livan Delgado-Roche et al.   FREE RADICAL BIOLOGY AND MEDICINE

Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-GD2immunotherapy and isotretinoin: a prospective Phase II study

(2015) Brian H Kushner et al.   OncoImmunology

Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma

(2014) Ami V. Desai et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Key role for myeloid cells: Phase II results of anti-GD2antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma

(2014) Nai-Kong V. Cheung et al.   INTERNATIONAL JOURNAL OF CANCER

Phase I Trial of a Novel Anti-GD2 Monoclonal Antibody, Hu14.18K322A, Designed to Decrease Toxicity in Children With Refractory or Recurrent Neuroblastoma

(2014) Fariba Navid et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting arterial wall sulfated glycosaminoglycans in rabbit atherosclerosis with a mouse/human chimeric antibody

(2014) Yosdel Soto et al.   mAbs

GD2-Targeted Immunotherapy and Radioimmunotherapy

(2014) Konstantin Dobrenkov et al.   SEMINARS IN ONCOLOGY

Ch14.18 antibody produced in CHO cells in relapsed or refractory Stage 4 neuroblastoma patients

(2013) Ruth Ladenstein et al.   mAbs

Murine Anti-GD2 Monoclonal Antibody 3F8 Combined With Granulocyte-Macrophage Colony-Stimulating Factor and 13-Cis-Retinoic Acid in High-Risk Patients With Stage 4 Neuroblastoma in First Remission

(2012) Nai-Kong V. Cheung et al.   JOURNAL OF CLINICAL ONCOLOGY

Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo

(2012) Nai-Kong V. Cheung et al.   OncoImmunology

Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

(2010) Alice L. Yu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pediatric Dosing and Body Size in Biotherapeutics

(2010) Rong Shi et al.   Pharmaceutics

Phase I and Pharmacokinetic Study of Cetuximab and Irinotecan in Children With Refractory Solid Tumors: A Study of the Pediatric Oncology Experimental Therapeutic Investigators' Consortium

(2009) Tanya M. Trippett et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: A Children's Oncology Group report

(2009) Anne L. Angiolillo et al.   PEDIATRIC BLOOD & CANCER

Phase I Trial and Pharmacokinetic Study of Bevacizumab in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Study

(2008) Julia L. Glade Bender et al.   JOURNAL OF CLINICAL ONCOLOGY

Infliximab Treatment of Intravenous Immunoglobulin–Resistant Kawasaki Disease

(2008) Jane C. Burns et al.   JOURNAL OF PEDIATRICS

Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients

(2007) Mark D. Pescovitz et al.   PEDIATRIC TRANSPLANTATION